SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Heterologous vaccination with a first dose of ChAdOx1-nCoV-19/AZD1222 and a second dose of BNT induces higher neutralizing antibody titers than the corresponding homologous vaccinations.
“Heterologous vaccination with a first dose of ChAdO1-nCoV-19/AZD1222 (AZ) (Voysey et al., 2021) and a second dose of BNT was shown to induce higher neutralizing antibody titers as compared with the corresponding homologous vaccinations”
From The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic (2022) · cites this paper as Behrens et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01449-9 · Cited by 425 · see citing works
Self-citationBorobia, A. M., Carcas, A. J., Pérez‐Olmeda, M., Castaño, L. A., Bertran, M. J., García‐Pérez, J., Campins, M., Portolés, A., González-Pérez, M., Morales, M. T. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01420-3 · Cited by 350 · see citing works
Hillus, D., Schwarz, T., Tober‐Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00357-x · Cited by 343 · see citing works
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
Normark, J., Vikström, L., Gwon, Y.-D., Persson, I.-L., Edin, A., Björsell, T., Dernstedt, A., Christ, W., Tevell, S., Evander, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2110716 · Cited by 158 · see citing works
Arora, P., Sidarovich, A., Krüger, N., Kempf, A. M., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., Schulz, S. R., Jäck, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109825 · Cited by 76 · see citing works
Self-citationHeterologous vaccine regimens against COVID-19
Duarte‐Salles, T., & Prieto‐Alhambra, D. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01442-2 · Cited by 33 · see citing works
Arora, P., Kempf, A. M., Nehlmeier, I., Sidarovich, A., Krüger, N., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., Schulz, S. R., Jäck, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.23.449568 · Cited by 20 · see citing works
Self-citation
Flagged first, then by citations
1 of the 9 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889 · see citing works
“Heterologous vaccinations with a first of dose of ChAdO1-nCoV-19/AZD1222 (AZ) (Voysey et al., 2021) and a second dose of BNT was shown to induce higher neutralizing antibody titers as compared to the corresponding homologous vaccinations (Barros-Martins et al., 2021; Behrens et al., 2021).”
Self-citationGroß, R. M., Zanoni, M., Seidel, A., Conzelmann, C., Gilg, A., Krnavek, D., Erdemci-Evin, S., Mayer, B., Hoffmann, M., Pöhlmann, S., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103761 · Cited by 137 · see citing works
Self-citationCurtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Kroger, A. T., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42372 · Cited by 120 · see citing works
Heterologous prime–boost strategies for COVID-19 vaccines
Sapkota, B., Saud, B., Shrestha, R., Al-Fahad, D., Sah, R., Shrestha, S., & Rodriguez-Morales, A. J. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab191 · Cited by 92 · see citing works
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 91 · see citing works
“Interestingly, heterologous prime-boost vaccination with an adenoviral vector prime followed by mRNA vaccination was superior to homologous vaccine schemes in inducing humoral and cellular immune responses [159 – 167].”
BackgroundEmerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications
Dubey, A., Choudhary, S., Kumar, P., & Tomar, S. (2021) · Current Microbiology · doi:10.1007/s00284-021-02724-1 · Cited by 79 · see citing works
Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Kroger, A. T., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42109 · Cited by 68 · see citing works
Klemis, V., Schmidt, T., Schub, D., Mihm, J., Marx, S., Abu‐Omar, A., Ziegler, L., Hielscher, F., Guckelmus, C., Urschel, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32321-0 · Cited by 42 · see citing works
Garreffa, E., Hamad, A., O'Sullivan, C. C., Hazim, A. Z., York, J., Puri, S., Turnbull, A. E., Robertson, J. F. R., & Goetz, M. P. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.033 · Cited by 43 · see citing works
“This strategy, which offers complementary stimulation of different immune pathways, also appears to produce a more potent immune response against variants of concern such as Beta [11,14] and Delta [15].”
Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
Nguyen, T. T., Quach, T. H. T., Tran, T. M., Phuoc, H. N., Nguyen, H. T., Vo, T. K., & Vo, G. V. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112650 · Cited by 41 · see citing works
“Behrens[31] ChAd/ BNTWith ChAd/ChAd 50% neutralization titers (NT50) ChAD/BNT induced higher levels against all type of variants compared to ChAd/ChAd group.”
MethodArora, P., Rocha, C., Kempf, A. M., Nehlmeier, I., Graichen, L., Winkler, M. S., Lier, M., Schulz, S. R., Jäck, H., Cossmann, A., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00779-5 · Cited by 36 · see citing works
Self-citationXu, K., Fan, C., Han, Y., Dai, L., & Gao, G. F. (2022) · International Immunology · doi:10.1093/intimm/dxac031 · Cited by 31 · see citing works
Vogel, E., Kocher, K., Priller, A., Cheng, C., Steininger, P. A., Liao, B., Körber, N., Willmann, A., Irrgang, P., Held, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104294 · Cited by 31 · see citing works
“8 Currently, it therefore remains unclear how the heterologous combination of ChAd and mRNA vaccination compares to homologous mRNA or ChAd vaccination in terms of persistence of humoral and cellular immunity.”
Masset, C., Ville, S., Garandeau, C., Leborgne, F., Letellier, T., Cantarovich, D., Meurette, A., Guillot-Gueguen, C., Bentoumi-Loaec, M., Giral, M., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.11.024 · Cited by 19 · see citing works
“demonstrated a higher immune response induced by a heterologous schedule, including neutralization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant.(7) To our knowledge, we report the first study assessing humoral responses to a heterologous vaccination schedule in immunocompromised KT…”
There is nothing exempt from the peril of mutation – The Omicron spike
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Anwer, M. K., Makeen, H. A., Albratty, M., Alhazmi, H. A., Bhatia, S., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112756 · Cited by 16 · see citing works
Andersson, N. W., Thiesson, E. M., Laursen, M. V., Mogensen, S. H., Kjær, J., & Hviid, A. P. (2022) · BMJ · doi:10.1136/bmj-2022-070483 · Cited by 12 · see citing works
Bauswein, M., Peterhoff, D., Plentz, A., Hiergeist, A., Wagner, R., Gessner, A., Salzberger, B., Schmidt, B., & Bauernfeind, S. (2022) · iScience · doi:10.1016/j.isci.2021.103694 · Cited by 9 · see citing works
Glycoprofile Comparison of the SARS-CoV-2 Spike Proteins Expressed in CHO and HEK Cell Lines
Wright, H. L., Evans, C. A., Jackson, P. J., James, D. C., Tee, K. L., Wong, T. S., Dickman, M. J., & Pandhal, J. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01288-2 · Cited by 6 · see citing works
“The spike protein became a focal target for diagnostic, treatment and vaccine development, and thus it is vital to fully understand the protein’s glycosylation profile in order to identify aspects of the SARS-CoV-2 biology that may influence future vaccine design [17, 19–21].”
Kang, C., Lee, N., Lin, C.-H., Hsu, Y., Chang, Y.-C., Chung, M., Lee, Y.-F., Tseng, W.-P., Wu, J.-L., Chen, S., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105156 · Cited by 6 · see citing works
Dimitroff, S. J., Würfel, L., Meier, M., Faig, K. E., Benz, A., Denk, B., Bentele, U. U., Unternäehrer, E., & Pruessner, J. C. (2023) · Biological Psychology · doi:10.1016/j.biopsycho.2023.108636 · Cited by 3 · see citing works
Anticuerpos neutralizantes, nuevas pruebas de laboratorio contra el SARS-CoV-2
Figueroa-Montes, L. E. (2022) · ACTA MEDICA PERUANA · doi:10.35663/amp.2021.384.2191 · Cited by 2 · see citing works
Absence of antibody responses to SARS-CoV-2 N protein in COVID-19 vaccine breakthrough cases
Vu, L. D., Wallace, S., Phan, A., Christofferson, R. C., Turner, E. A., Parker, S., Elkind-Hirsch, K. E., Landry, D., Stansbury, A., Rose, R., et al. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221134097 · Cited by 2 · see citing works
Yi, B., Laubner, A., Stadtmüller, M., Patrasová, E., Šimůnková, L., Rost, F., Winkler, S., Reinhardt, S., Dahl, A., & Dalpke, A. H. (2024) · Epidemiology and Infection · doi:10.1017/s0950268824000761 · Cited by 2 · see citing works
Effect of Covid-19 Vaccines Against Delta Variant. A Review Article
Raslan, M. A., Eslam, M. S., Sara, A. R., & Sabri, N. A. (2022) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2022.06.0849 · Cited by 1 · see citing works
Neutralisation de Sars-CoV-2 Delta après vaccination hétérologue
Manus, J.-M. (2021) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(21)00232-x
Wi(e)der SARS-CoV-2: Epidemiologie, Booster und Impfstoffkombis
Welte, T. (2021) · Pneumo News · doi:10.1007/s15033-021-2785-x
“Inzwischen gibt es eine Reihe von Untersuchungen, die zeigt, dass die heterologe Impfung im Hinblick auf die Antikörperentwicklung der homologen Impfung mindestens gleichwertig, wenn nicht überlegen ist ([8, 9], ▶Abb.”
BackgroundKhan, R. A., Chen, J., Donius, L. R., Reinherz, E. L., & Kim, M. (2026) · npj Vaccines · doi:10.1038/s41541-026-01371-6
“Boosting strategies are important to provide additional antigenic stimulation, facilitating the re fi nement of the antibody repertoire to enhance neutralization potency and breadth 54,55 .”
- Authors
- Behrens, G. M., Cossmann, A., Stankov, M. V., Nehlmeier, I., Kempf, A., Hoffmann, M., & Pöhlmann, S.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- German Primate Center (DE)
- Corresponding author
- Behrens, Georg MN
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 398
- Issue
- 10305
- Pages
- 1041-1042
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC8372487
- OpenAlex
- W3193400296
- Cited by
- 27
- References
- 9
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 2 · 2022: 13 · 2021: 9
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, other-oa)
- Funders
- Bundesministerium für Bildung und Forschung
- Niedersächsisches Ministerium für Wissenschaft und Kultur
- Deutsches Zentrum für Infektionsforschung
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- Delta variant, neutralizing antibodies, heterologous booster, ChAdOx1 nCoV-19 vaccine, BNT162b2, mRNA-1273, COVID-19 vaccines, vaccine safety, reactogenicity, immune response
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Humans, Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
